加拿大多倫多大學吳教授學術報告

報告題目：Advances in the Design of Nanomedicine for Enhancing Cancer Therapies

報告人：Professor Xiao Yu (Shirley) Wu

FAAPS Director of Advanced Pharmaceutics & Drug Delivery Laboratory, Leslie Dan Faculty of Faculty of Pharmacy, University of Toronto, Ontario, Canada

主持人：陳永明  教授

時間：2017年11月16日（星期四）下午15：30

地點：豐盛堂芙蘭學術交流中心A402

歡迎廣大師生參加！

摘要：

Chemotherapy is a main treatment of malignant tumors and metastatic cancer.  However, drug resistance of cancer cells and drug-induced normal tissue toxicity limit the success of the treatment. Drug resistance is multifactorial involving numerous molecular, cellular, and non-cellular mechanisms. Similarly radiation therapy, a major therapy received by over 50% of cancer patients, encounters tremendous tumor resistance due to hypoxic tumor microenvironment (TME) and hypoxia-induced factors. To tackle multifaceted resistance mechanisms, Dr. Wu’s group has designed various novel nanoparticle systems by exploiting tumor selective bioreactivity of nanomaterials, intracellular synergistic drug-drug interactions and bioreactions of nanomaterial and drugs. These nanoparticle formulations significantly enhanced efficacy against multidrug resistant cancer cells while dramatically reducing systemic toxicity in preclinical tumor models. Her laboratory has devised and applied for the first time pharmaceutically acceptable hybrid manganese dioxide nanoparticles and demonstrated their selective activity to modulate TME and overcome hypoxia-induced resistance to radiotherapy. In this presentation, Dr. Wu will provide an overview of the design concepts, underlying bioreaction mechanisms, and the therapeutic benefits of these nanomedicine systems.